Belovezhdov N, Robeva R, Dimitrova V
Vutr Boles. 1990;29(6):29-35.
The survival rate of 68 patients with immunoglobulin A glomerulonephritis (IgA GN), 29 patients with membranous glomerulonephritis (MGN), 13 patients with membranous-proliferative glomerulonephritis (MPGN) and 40 patients with lupus glomerulonephritis (LGN) was assessed using the life registration tables. The patients with IgA GN were treated symptomatically, and the remaining patients were treated with a combination of corticosteroids, immunosuppressors and anticoagulants. At the 10th year from the onset of the disease the survival rate was as follows: for the patients with IgA GN--88%, with MGN--94.9%, with LGN--81.0% and with MPGN--61.6%. The comparison with the survival rate established for the respective types of glomerulonephritis without treatment or the presence of mixed groups of treated and nontreated patients shows that the combined pathogenetic treatment improves the prognosis of MGN, LGN and of a number of patients with MPGN and it nears that of the comparatively more benign IgA GN.
采用寿命登记表评估了68例免疫球蛋白A肾小球肾炎（IgA GN）患者、29例膜性肾小球肾炎（MGN）患者、13例膜增生性肾小球肾炎（MPGN）患者和40例狼疮性肾小球肾炎（LGN）患者的生存率。IgA GN患者接受对症治疗，其余患者接受皮质类固醇、免疫抑制剂和抗凝剂联合治疗。在疾病发病后的第10年，生存率如下：IgA GN患者为88%，MGN患者为94.9%，LGN患者为81.0%，MPGN患者为61.6%。与未治疗的各型肾小球肾炎或治疗与未治疗患者混合组所确定的生存率相比，表明联合病因治疗改善了MGN、LGN以及一些MPGN患者的预后，使其接近相对良性的IgA GN的预后。
